Harnessing LPAR3 as a Novel Approach to Transform Alzheimer’s & Neurodegenerative Disease Treatment
- Unlocking the therapeutic promise of ADS024, a single-strain, orally delivered live biotherapeutic product, by demonstrating efficacy across Alzheimer’s and multiple neuroinflammatory and neurodegenerative disease models through LPAR3 agonism
- Exploring the gut–brain axis with a focus on ADS024’s impact on neuroinflammation, gut-derived signalling, and implications for disease progression
- Positioning LPAR3 as an underexplored GPCR target within the EDG/S1P receptor family, with genetic ties to Alzheimer’s biomarkers and strong potential for novel, accessible neuroinflammation therapies